Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 662-667

  Knutsen, Lars J S ^a   Hobbs, Christopher J ^a   Earnshaw, Christopher G ^a   Fiumana, Andrea ^a   Gilbert, Jenny ^a   Mellor, Sarah L ^a   Radford, Fleur ^a   Smith, Nichola J ^a   Birch, Philip J ^a   Russell Burley, J ^a   Ward, Stuart D C ^a   James, Iain F ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

Analgesia; N type calcium channel; Thiazolidinone

Indexed keywords

2 (3 BROMO 4 FLUOROPHENYL) 3 (2 PYRIDIN 2 YLETHYL)THIAZOLIDIN 4 ONE; CALCIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NEUROPATHIC PAIN; STRUCTURE ACTIVITY RELATION;

ANALGESICS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; HUMANS; INDICATORS AND REAGENTS; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 33846377544     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.098     Document Type: Article

References (37)

1. Gribkoff V.K., and Starrett J.E. Expert Opin. Pharmacother. 1 (1999) 61
2. Cox B., and Denyer J.C. Expert Opin. Ther. Patents 8 (1998) 1237
3. Elmslie K.S. J. Neurosci. Res. 75 (2004) 733
4. Spafford J.D., and Zamponi G.W. Curr. Opin. Neurobiol. 13 (2003) 308
5. Catterall W.A. Cell Calcium 24 (1998) 307
6. Dickenson A.H., Matthews E.A., and Diaz A.M. Pain (2003) 619
7. Sabido-David C., Faravelli L., and Salvati P. Expert Opin. Investig. Drugs 13 (2004) 1249
8. McGivern J.G., and McDonough S.I. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 457
9. Saegusa H., Kurihara T., Zong S., Kazuno A., Matsuda Y., Nonaka T., Han W., Toriyama H., and Tanabe T. EMBO J. 20 (2001) 2349
10. Miljanich G.P. Curr. Med. Chem. 11 (2004) 3029
11. Matthews E.A., and Dickenson A.H. Pain 92 (2001) 235
12. Atanassoff P.G., Hartmannsgruber M.W.B., Thrasher J., Wermeling D., Pharm D., Longton W., Gaeta R., Singh T., Mayo M., McGuire D., and Luther R.R. Reg. Anesth. Pain. Med. 25 (2000) 274
13. Sills G.J. Curr. Opin. Pharmacol. 6 (2006) 108;
14. Canti C., Davies A., and Dolphin A.C. Curr. Neuropharmacol. 1 (2003) 209
15. Stahl S.M. J. Clin. Psychiatry 65 (2004) 1033
16. Pauwels P.J., Leysen J.E., and Janssen P.A.J. Life Sci. 48 (1991) 1881
17. Hara H., Morita T., Sukamoto T., and Cutrer F.M. CNS Drug Rev. 1 (1995) 204
18. Snutch, T. P. PCT Int. Appl. WO 01/45709, 2001
19. Chem. Abstr. 135 (2001) 61354
20. Song Y., Bowersox S.S., Connor D.T., Dooley D.J., Lotarski S.M., Malone T., Miljanich G., Millerman E., Rafferty M.F., Rock D., Roth B.D., Schmidt J., Stoehr S., Szoke B.G., Taylor C., Vartanian M., and Wang Y.-X. J. Med. Chem. 43 (2000) 3474
21. Chapdelaine, M.; Kemp, L.; McCauley, J. PCT Int. Appl. WO 02/36567, 2002
22. Chem. Abstr. 136 (2002) 369614
23. Takahara A., Fujita S., Moki K., Ono Y., Koganei H., Iwayama S., and Yamamoto H. Hypertens. Res. 26 (2003) 743
24. Sun Q., Tafesse L., Limberis J.T., Islam K., and Kyle D.J. Comb. Chem. High Throughput Screening 6 (2003) 481
25. Sun, Q.; Kyle, D. J. PCT Int. Appl. WO 03/008398, 2003
26. Chem. Abstr. 138 (2003) 131144
27. Kato T., Ozaki T., Tamura K., Suzuki Y., Akima M., and Ohi N. J. Med. Chem. 42 (1999) 3134
28. Castle, N. A.; Gross, M.; Mendoza, J. S. PCT Int. Appl. WO 99/62891, 1999
29. Chem. Abstr. 132 (1999) 12317
30. Knutsen, L. J. S.; Hobbs, C. J.; Radford, F.; Fiumana, A. PCT Int. Appl. WO 04/17965, 2004
31. Chem. Abstr. 140 (2004) 217639
32. Knutsen, L. J. S.; Hobbs, C. J.; Radford, F.; Fiumana, A.; Earnshaw, C. G.; Mellor, S. L.; Smith, N. J. PCT Int. Appl. WO 04/17966, 2004
33. Chem. Abstr. 140 (2004) 217640
34. Thomas A.D., and Asokan C.V. J. Chem. Soc., Perkin Trans. 1 20 (2001) 2583
35. Lohse O., Thevenin P., and Waldvogel E. Synlett 1 (1999) 45
36. 50 values: ω-Conotoxin GVIA: 8.42 ± 0.22 at N-type, no measurable block at L-type. Nimodipine: 4.97 ± 0.26 at N-type and 7.87 ± 0.27 at L-type. See Ward, S. D. C.; Hick, C. A.; Thomas, D. Online Abstract Viewer/Itinerary Planner, Society for Neuro-science Annual Meeting, New Orleans, Louisiana, November 8-12, 2003; Society for Neuroscience, Washington, DC; Program No. 165.7.
37. ® OD-H; mobile phase-95% heptane/5% isopropanol; UV detection at 225 nm. Flow rate-1 ml/min, at 25 °C.